Abstract
Purpose: To investigate the in vitro pharmacokinetics of sirolimus-coated stent for tracheal stenosis Methods: Naked nickel titanium alloy stent was placed in methylene chloride leaching solution with different ratios of sirolimus/poly(lactic-co-glycolic acid) (PLGA). The morphology, thickness, and pellicles on the surface of the stent were observed by scanning electronic microscopy. Drug release from the stent was determined by enzyme amplification immunoassay. Results: Sirolimus was smoothly and uniformly attached to the stent, with an optimal sirolimus: PLGA coating ratio of 1:10. Further increases in sirolimus: PLGA ratio did not improve stent drug loading. A slow release of sirolimus from the stent was observed in the first week, followed by a rapid release and then much slower release process. Release of sirolimus persisted in the stent throughout the period of 42 days. Conclusion: The sirolimus-coated stent has a good surface morphology, and sustained and effective drug release characteristics. Thus, it may be effective and safe for use in the treatment of tracheal stenosis in vivo . Keywords: Tracheal stenosis, Sirolimus, Drug-coated stents, poly(lactic-co glycolic acid) PLGA
Highlights
Tracheal stenosis is a congenital or secondary disease caused by infection, cancer, trauma, or endometrial tuberculosis
Drug-coated stents prepared at different sirolimus/poly(lactic-co-glycolic acid) (PLGA) ratios presented different drug loading profiles (Table 1)
Maximum drug loading of stent was obtained at sirolimus/PLGA ratio of 1:10
Summary
Tracheal stenosis is a congenital or secondary disease caused by infection, cancer, trauma, or endometrial tuberculosis. Clinical manifestations of tracheal stenosis include cough, expectoration, dyspnea and respiratory failure. Stent implantation quickly relieves the dyspnea and improves the quality of patient’s life [1]. Intratracheal stent can damage the airway mucosa, and cause excessive proliferation of fibrous tissue. These lead to stent restenosis, which seriously affects the clinical efficacy of stent implantation [3]. Clinically-applied drug-eluting stent (DES) has been used in a wide range of patients with cardiopathy, gastroenteropathy or urologic diseases [4,5]. Research on applications of DES in tracheal stenosis treatment is still limited
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
